One in three bacterial infections reported across the WHO South-East Asian and Eastern Mediterranean regions were resistant to antibiotic treatment in 2023. More than 40% of E. coli and over 55% of Klebsiella pneumoniae are now resistant to third-generation cephalosporins, moving demand toward the carbapenems and the last-line injectables behind them.
Where third-generation cover fails, the next lines are 27 carbapenem presentations and seven in the polymyxin class.
Range depth
Four carbapenems, the complete set.
Tell us the market and what you already stock.
Start the conversation